BioCentury
ARTICLE | Company News

Vivalis, GlaxoSmithKline, Texas A&M University System, U.S. Department of Health and Human Services infectious, biomanufacturing news

April 1, 2013 7:00 AM UTC

GlaxoSmithKline and the university announced that HHS has approved the establishment of a $91 million influenza-vaccines manufacturing facility in Bryan-College Station, Texas. The pharma said the center will allow it the ability to eventually manufacture influenza vaccine based on the EB66 cell line, which is derived from duck embryonic stem cells. In 2007, GSK partnered with Vivalis to use the biotech's avian embryonic stem cell-derived EBx cell lines and related technology to produce seasonal and pandemic human flu vaccines (see BioCentury, June 4, 2007). ...